Novel approach to overcome malignant cancer by targeting Y-box binding protein-1(YB-1)

HER 2过表达是胃癌患者预后不良的预测因素。目前，HER 2靶向抗体曲妥珠单抗（trastuzumab）已提高了HER 2阳性晚期胃癌的治疗效果。这项研究表明，Y-box结合蛋白-1（YB-1）敲低抑制了HER 2的表达，影响了胃癌细胞对拉帕替尼（EGFR和HER 2的双重激酶抑制剂）的耐药性。此外，细胞核YB-1的表达也与HER 2的表达在人胃癌中特异性相关。因此，YB-1-HER 2轴可能有助于进一步开发针对HER 2的胃癌个性化治疗药物。

HER2 overexpression is a predictive factor of poor prognosis in patients with gastric cancer. Currently, the HER2-targeted antibody, trastuzumab, has improved the efficacy of therapy for HER2-positive advanced stomach cancer. This study demonstrated that Y-box binding protein-1 (YB-1) knockdown suppressed the expression of HER2, affecting drug resistance to lapatinib, a dual kinase inhibitor of EGFR and HER2, in gastric cancer cells. Moreover, nuclear YB-1 expression was also specifically correlated with expression of HER2 in human gastric cancer. YB-1-HER2 axis could thus contribute to further development of personalized therapeutics by HER2-targeted drugs against gastric cancer.